275 related articles for article (PubMed ID: 33276788)
1. The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Ballotti R; Cheli Y; Bertolotto C
Mol Cancer; 2020 Dec; 19(1):170. PubMed ID: 33276788
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Tirosh I; Izar B; Prakadan SM; Wadsworth MH; Treacy D; Trombetta JJ; Rotem A; Rodman C; Lian C; Murphy G; Fallahi-Sichani M; Dutton-Regester K; Lin JR; Cohen O; Shah P; Lu D; Genshaft AS; Hughes TK; Ziegler CG; Kazer SW; Gaillard A; Kolb KE; Villani AC; Johannessen CM; Andreev AY; Van Allen EM; Bertagnolli M; Sorger PK; Sullivan RJ; Flaherty KT; Frederick DT; Jané-Valbuena J; Yoon CH; Rozenblatt-Rosen O; Shalek AK; Regev A; Garraway LA
Science; 2016 Apr; 352(6282):189-96. PubMed ID: 27124452
[TBL] [Abstract][Full Text] [Related]
4. Melanoma Single-Cell Biology in Experimental and Clinical Settings.
Binder H; Schmidt M; Loeffler-Wirth H; Mortensen LS; Kunz M
J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33535416
[TBL] [Abstract][Full Text] [Related]
5. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.
Fischer GM; Vashisht Gopal YN; McQuade JL; Peng W; DeBerardinis RJ; Davies MA
Pigment Cell Melanoma Res; 2018 Jan; 31(1):11-30. PubMed ID: 29049843
[TBL] [Abstract][Full Text] [Related]
6. Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.
Kupcova Skalnikova H; Cizkova J; Cervenka J; Vodicka P
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236046
[TBL] [Abstract][Full Text] [Related]
7. The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response.
Cabrita R; Mitra S; Sanna A; Ekedahl H; Lövgren K; Olsson H; Ingvar C; Isaksson K; Lauss M; Carneiro A; Jönsson G
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245160
[TBL] [Abstract][Full Text] [Related]
8. Voices: Challenges and opportunities in regulating the immune system.
Chen Y; Humphries F; Li MO; Kanneganti TD; Ye D
Cell Chem Biol; 2024 May; 31(5):830-832. PubMed ID: 38759615
[TBL] [Abstract][Full Text] [Related]
9. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
[TBL] [Abstract][Full Text] [Related]
10. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
[TBL] [Abstract][Full Text] [Related]
11. MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role.
Hsiao YJ; Chang WH; Chen HY; Hsu YC; Chiu SC; Chiang CC; Chang GC; Chen YJ; Wang CY; Chen YM; Lin CY; Chen YJ; Yang PC; Chen JJW; Yu SL
Aging (Albany NY); 2020 Dec; 13(1):646-674. PubMed ID: 33293474
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Ribas A; Algazi A; Ascierto PA; Butler MO; Chandra S; Gordon M; Hernandez-Aya L; Lawrence D; Lutzky J; Miller WH; Campbell KM; Delafont B; Marshall S; Mueller N; Robert C
Nat Commun; 2020 Dec; 11(1):6262. PubMed ID: 33288749
[TBL] [Abstract][Full Text] [Related]
13. STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.
Swoboda A; Soukup R; Eckel O; Kinslechner K; Wingelhofer B; Schörghofer D; Sternberg C; Pham HTT; Vallianou M; Horvath J; Stoiber D; Kenner L; Larue L; Poli V; Beermann F; Yokota T; Kubicek S; Krausgruber T; Rendeiro AF; Bock C; Zenz R; Kovacic B; Aberger F; Hengstschläger M; Petzelbauer P; Mikula M; Moriggl R
Oncogene; 2021 Feb; 40(6):1091-1105. PubMed ID: 33323974
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA: metabolism, functions and interactions with proteins.
Zhou WY; Cai ZR; Liu J; Wang DS; Ju HQ; Xu RH
Mol Cancer; 2020 Dec; 19(1):172. PubMed ID: 33317550
[TBL] [Abstract][Full Text] [Related]
15. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso CS; Tsoi J; Onyshchenko M; Abril-Rodriguez G; Ross-Macdonald P; Wind-Rotolo M; Champhekar A; Medina E; Torrejon DY; Shin DS; Tran P; Kim YJ; Puig-Saus C; Campbell K; Vega-Crespo A; Quist M; Martignier C; Luke JJ; Wolchok JD; Johnson DB; Chmielowski B; Hodi FS; Bhatia S; Sharfman W; Urba WJ; Slingluff CL; Diab A; Haanen JBAG; Algarra SM; Pardoll DM; Anagnostou V; Topalian SL; Velculescu VE; Speiser DE; Kalbasi A; Ribas A
Cancer Cell; 2021 Jan; 39(1):122. PubMed ID: 33306984
[No Abstract] [Full Text] [Related]
16. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS.
Cunningham KM; Maulding K; Ruan K; Senturk M; Grima JC; Sung H; Zuo Z; Song H; Gao J; Dubey S; Rothstein JD; Zhang K; Bellen HJ; Lloyd TE
Elife; 2020 Dec; 9():. PubMed ID: 33300868
[TBL] [Abstract][Full Text] [Related]
17. α-MSH-PE38KDEL Kills Melanoma Cells via Modulating Erk1/2/MITF/TYR Signaling in an MC1R-Dependent Manner.
Liu X; Li H; Cong X; Huo D; Cong L; Wu G
Onco Targets Ther; 2020; 13():12457-12469. PubMed ID: 33299329
[TBL] [Abstract][Full Text] [Related]
18. Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.
Lin Z; Meng X; Wen J; Corral JM; Andreev D; Kachler K; Schett G; Chen X; Bozec A
Front Oncol; 2020; 10():596493. PubMed ID: 33344244
[TBL] [Abstract][Full Text] [Related]
19. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
20. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
